Format

Send to

Choose Destination
Biochemistry. 2007 Jan 9;46(1):156-63.

Human glycinamide ribonucleotide transformylase: active site mutants as mechanistic probes.

Author information

1
Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati Medical Center, P.O. Box 670004, Cincinnati, Ohio 45267, USA.

Abstract

Human glycinamide ribonucleotide transformylase (GART) (EC 2.1.2.2) is a validated target for cancer chemotherapy, but mechanistic studies of this therapeutically important enzyme are limited. Site-directed mutagenesis, initial velocity studies, pH-rate studies, and substrate binding studies have been employed to probe the role of the strictly conserved active site residues, N106, H108, and D144, and the semiconserved K170 in substrate binding and catalysis. Only two conservative substitutions, N106Q and K170R, resulted in catalytically active enzymes, and these active mutant enzymes gave pH-rate profiles and a steady-state kinetic mechanism essentially identical to those of the native enzyme. All inactive mutants were able to bind both substrates, ruling out disrupted formation of the ternary complex as the source of inactivity. Differences between human and Escherichia coli GART, previously used as a model for the human enzyme, were evident.

PMID:
17198385
PMCID:
PMC2518408
DOI:
10.1021/bi0619270
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center